文献速递冠心病心力衰竭与心肌病血脂与心血管预防

代谢手术与既往心肌梗死合并重度肥胖患者主要不良心血管结局的关联:一项全国性队列研究

Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Severe Obesity: A Nationwide Cohort Study.
PubMed 文献 · Circulation · 2020-10-26

该研究基于瑞典SWEDEHEART和SOReg登记数据,将509例既往心肌梗死合并重度肥胖且接受代谢手术的患者与509例仅心肌梗死无手术患者1:1匹配,随访中位4.6年。代谢手术组8年主要不良心血管事件累积概率为18.7%,低于对照组的36.2%(校正HR 0.44,95%CI 0.32-0.61),死亡和新发心肌梗死风险亦降低。

要点

  • 既往心肌梗死合并重度肥胖患者接受代谢手术与主要不良心血管事件风险降低相关(校正HR 0.44)。
  • 代谢手术组死亡风险(校正HR 0.45)和新发心肌梗死风险(校正HR 0.24)均较低。
  • 卒中(HR 0.91)和新发心房颤动(HR 0.56)风险无显著差异。

核心结论

  • 在既往心肌梗死合并重度肥胖患者中,代谢手术与严重并发症风险低、主要不良心血管事件、死亡、新发心肌梗死和新发心力衰竭风险降低相关。
  • 上述发现需随机对照试验证实。

研究设计与样本

  • 全国性队列研究,基于SWEDEHEART和Scandinavian Obesity Surgery Registry登记数据。
  • 509例既往心肌梗死接受代谢手术患者(Roux-en-Y胃旁路术465例,袖状胃切除术44例)与509例既往心肌梗死未行代谢手术对照1:1匹配。
  • 匹配因素包括性别、年龄(±3岁)、心肌梗死年份(±3年)和体重指数(±3)。

主要发现

  • 中位随访4.6年(四分位距2.7-7.1年)。
  • 代谢手术组8年主要不良心血管事件累积概率为18.7%(95%CI 15.9-21.5%),对照组为36.2%(95%CI 33.2-39.3%),校正HR 0.44(95%CI 0.32-0.61)。
  • 代谢手术组死亡校正HR 0.45(95%CI 0.29-0.70),新发心肌梗死校正HR 0.24(95%CI 0.14-0.41)。
  • 代谢手术组新发心力衰竭风险较低。
  • 卒中校正HR 0.91(95%CI 0.38-2.20)和新发心房颤动校正HR 0.56(95%CI 0.31-1.01)无显著差异。

临床怎么用

  • 对于既往心肌梗死合并重度肥胖的患者,代谢手术可能作为降低主要不良心血管事件风险的策略之一。
  • 临床决策时应结合患者个体情况,并考虑代谢手术的严重并发症风险较低。

局限性

  • 代谢手术组心肌梗死后射血分数降低比例较低(7% vs 12%),既往心力衰竭(10% vs 19%)、心房颤动(6% vs 10%)和慢性阻塞性肺疾病(4% vs 7%)比例亦较低。
  • 研究为观察性设计,结论需随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The number of patients with myocardial infarction and severe obesity is increasing and there is a lack of evidence how these patients should be treated. The aim of this study was to investigate the association between metabolic surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) and major adverse cardiovascular events in patients with previous myocardial infarction (MI) and severe obesity. METHODS: Of 566 patients with previous MI registered in the SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) undergoing metabolic surgery and registered in the nationwide Scandinavian Obesity Surgery Registry, 509 patients (Roux-en-Y gastric bypass n=465; sleeve gastrectomy n=44) could be matched 1:1 to a control with MI from SWEDEHEART, but no subsequent metabolic surgery regarding sex, age (±3 years), year of MI (±3 years), and body mass index (±3). The 2 groups were well matched, except for a lower proportion of reduced ejection fraction after MI (7% versus 12%), previous heart failure (10% versus 19%), atrial fibrillation (6% versus 10%), and chronic obstructive pulmonary disease (4% versus 7%) in patients undergoing metabolic surgery. RESULTS: The median (interquartile range) follow-up time was 4.6 (2.7-7.1) years. The 8-year cumulative probability of major adverse cardiovascular events was lower in patients undergoing metabolic surgery (18.7% [95% CI, 15.9-21.5%] versus 36.2% [33.2-39.3%], adjusted hazard ratio, 0.44 [95% CI, 0.32-0.61]). Patients undergoing metabolic surgery had also a lower risk of death (adjusted HR, 0.45 [95% CI, 0.29-0.70]; MI, 0.24 [0.14-0.41]) and new onset heart failure, but there were no significant differences regarding stroke (0.91 [0.38-2.20]) and new onset atrial fibrillation (0.56 [0.31-1.01]). CONCLUSIONS: In severely obese patients with previous MI, metabolic surgery is associated with a low risk for serious complications, lower risk of major adverse cardiovascular events, death, new MI, and new onset heart failure. These findings need to be confirmed in a randomized, controlled trial.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Näslund E, Stenberg E, Hofmann R, et al. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Severe Obesity: A Nationwide Cohort Study. Circulation. 2020. PMID: 33103469. doi:10.1161/CIRCULATIONAHA.120.048585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。